For this site to function correctyl, you must enable javascript.

European Found for Regional Development

Optimization of extraction and drying parameters for fungal nutritional supplements (15.1. 2024 – 15.1. 2025)

Two partners’ project, MycoMedica Ltd and TurboEnergetika Ltd  has been selected as one of 9 among 58 submitted for funding through the HIGHFIVE initiative tender. This selection highlights the project’s significant potential and relevance in today’s agri-food industry.

The project with the acronym OEDFS represents a project of interdisciplinary integration and cooperation approach to apply, consolidate and deploy a technology of digital twin to the sector of the processing of medicinal fungi for nutritional supplements, with the introduction of a new system of sensors use, automation and digitization of the extraction and drying processes in the company MycoMedica Ltd. The main development goal of the OEDFS project is the optimization of the extraction and drying process for the production of nutritional supplements from medicinal fungi.

Medicinal fungi food supplements are gaining a reputation as immune system enhancers, antivirals, antibacterial and in the last time, as medicines for neurological diseases, as are Alzheimer’s disease, dementia, and multiple sclerosis. It is very important how these products are produced and how many medicinal compounds they contain. This project aims to optimize medicinal compound extraction and make products better and at the same time, improve production traceability, reduce energy consumption, reduce time consumption and not least, reduce their cost.

 #Innovation #AgriFoodTech #DigitalTransformation #Sustainability #EuropeanAgriFood #HIGHFIVEProject #EUFunded #DigitalTwin #agrifoodinnovation #foodindustry #twintransition #sustainabiliy #mycomedica #turboenergetika

This project has received funding under the European Union’s I3 programme under grant agreement 101083989.

eRECYn project – Sustainable production of standardized nutritional supplements from Hericium fungus (01.11.2022 – 30.11.2024)

The aim of the project is to develop a nutritional supplement from the medicinal fungus Hericium erinaceus in an innovative formulation, which will be the first in the world to have a standardized and declared content of the main neuroprotective agent, erinacin A. The final product will be developed and marketed as a raw material and as a final product under
GOBA brand. This product will be a high-quality food supplement produced from 100% biologically certified ingredients. The main project goal is the development of a completely new product, which will represent an exceptional innovation on the market of natural food supplements. With the new, innovative process, which will be fully optimized as part of the research and development activities during the project, we will fully utilize the active medicinal substances that are found in abundance in the extraction residues, while at the same time reducing the amount of waste. At the same time, the production process itself will be optimized to the extent that it will be extremely energy efficient. During the production process we will use waste heat from existing production processes instead of electricity. With the mentioned innovative approaches in production, we will greatly contribute to the transition to a circular economy, including mitigating climate change, and thus achieve a high level of technological neutrality. As part of the innovative research and development project, we will carry out a series of R&D activities that will fully optimize the production process. We will introduce completely new technological processes into the production process itself, which will be necessary for the efficient use of extraction residues from existing production as raw materials for obtaining extracts of active medicinal substances. These processes are not yet known and introduced into standard process procedures in the medicinal mushroom dietary supplement industry, so they will represent a global innovation in this field. The project will enable the development of a completely new product, for which it will be necessary to optimize the production processes both at the laboratory, as well as at the pilot and industrial level. The project takes place in the partnership of MycoMedica Ltd and PharmaHemp Ltd.

The total value of the project is 539,164 EUR, the value of co-financing is 299,981 EUR.

»The investment is part of the measures of the Slovenian plan, financed by the Recovery and Resilience Mechanism«

Link: webpage of plan

Digital transformation of MycoMedica Ltd

As part of the public call for incentives for the digital transformation of SMEs (P4D ReactEU), announced by the Public Fund of the Republic of Slovenia for Entrepreneurship, we at MycoMedica Ltd successfully obtained funds for the co-financing of the “Digital transformation of MycoMedica Ltd ” operation.


to encourage the growth and development of supported companies and the
elimination of the consequences of the Covid-19 pandemic based on investments in the use of digital business in their supply and/or sales chains, the increase of management capacities, the introduction of digital business models, the implementation of investments for the purposes of digital transformation in the production and operations of supported companies, increasing added value per employee and maintaining jobs in supported companies.


Implementation of digital transformation in supported companies, namely
through the implemented transition to digitization of operations and adaptation to digital markets, improving the competences of employees in supported companies, promotion of energetically and materially efficient processes and increasing added value per employee in supported companies.

Total project value: 166,665.55 EUR

Co-financing amount: 99.999,33 EUR

“The investment is co-financed by the Republic of Slovenia and the European Union from the European Fund for Regional Development”

ErinacinA project – The first dietary supplement standardized to erinacin A (9.7.2020 –8.7.2022)

The goal of the project is to develop a nutritional supplement made from medical mushrooms of the Hericium species, which will be the first on the world market to have a standardized and declared content of the key pharmacologically active ingredient in the mushroom – erinicin A. It is a bioactive ingredient of completely natural origin, which has been proven to act as a stimulator of the secretion of nerve growth factor a factor on the basis of which scientific studies attribute to it great potential in the treatment of modern neurodegenerative diseases. We will offer the product on the market in the form of raw material intended for manufacturers of nutritional supplements, and in the form of a finished product intended for end users. It is a high-quality food supplement, produced from 100% organically produced raw materials, which does not contain allergens and is also suitable for vegans. The product represents a global innovation in the field of nutritional supplements made from medicinal mushrooms, as there are currently no available products from this mushroom on the market in which the content of erinacin A is precisely determined and declared. The project takes place in the partnership of MycoMedica Ltd and PharmaHemp Ltd.

“The investment is co-financed by the Republic of Slovenia and the European Union from the European Regional Development Fund (ERDF).”

CoPro project – The first standardized dietary supplement from the medicinal mushroom Cordyceps (6.2.2018 – 6.2.2020)

As part of the project, we will develop a new natural food supplement made from medicinal fungi of the Cordyceps species, which will be the first food supplement with a high and as well standardized content of the pharmacologically active substance – cordycepin. The latest scientific research has confirmed the positive effects of cordycepin in the treatment and prevention of many diseases and its beneficial effect on general well-being. That is why there is currently a high demand for these types of food supplements from manufacturers and end users. The result of the project will be a new form of the product, which we will market to manufacturers of nutritional supplements in the form of raw materials and as dietary supplements under our own brand. With innovative analytical approaches, we will be the first to control the cordycepin content both during the fungal cultivation process and in the final products. This will ensure a high level of safety, quality and effectiveness of our product, which is currently still a rarity in the field of dietary supplements. By optimizing production on an industrial level, we will significantly reduce the cost of raw material production, which in turn means a more affordable product for both manufacturers of nutritional supplements and end users. The project is aimed at the production of food supplements that are also suitable for vegans, which we will achieve with the selection of 100% organic raw materials with the highest level of traceability. With such an approach,
our product is of high quality, safe, effective, affordable and therefore commercially interesting to manufacturers and end users of such nutritional supplements. The project takes place in the partnership of MycoMedica Ltd and Kobis Ltd.

“The investment is co-financed by the Republic of Slovenia and the European Union from the European Regional Development Fund (ERDF).”